• Conference
  • biomodal presenter
  • In partnership with Illumina

American Association for Cancer Research® (AACR) Annual Meeting 2025

Reveal the power of the 6-base genome. Introducing duet multiomics solution evoC. Distinguish 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) together with all four canonical bases to measure multiple modes of biology from a single low-input DNA sample in a single experiment. Identify novel multimodal biomarkers to gain transformative insights into current and future states of disease.
25 April 2025
to 30 April 2025
McCormick Place Convention Center
, Chicago

Visit biomodal at booth 

#2709

Presentations

Explore our resources

Register now

About the event

Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact

The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting showcases cutting-edge cancer science and medicine.

Presenting at the event

From Discovery to Collaboration: Providing Insights Into Epigenetic Mechanisms Impacting Genome Stability

Johnathan R. Whetstine, PhD

Director, Cancer Epigenetics Institute Co-leader, Nuclear Dynamics and Cancer Program Fox Chase Cancer Center

Fox Chase Cancer Center & Cancer Epigenetics Institute

Sunday, April 27th, 2025 | 1:30PM-2:30PM | Spotlight Theater D.

The talk will highlight how collaboration between the Cancer Epigenetics Institute and biomodal resulted in novel research opportunities. Furthermore, we will highlight how our studies have uncovered unappreciated mechanisms controlling DNA amplification and rearrangements.

Epigenetic inhibitor decitabine expands a novel therapeutic strategy in pancreatic cancer

Zachery Keepers

Medical Student

University of Maryland School of Medicine, Department of Radiation Oncology

Sunday, April 27th, 2025 | 1:30PM-2:30PM | Spotlight Theater D.

Patient-derived pancreatic cancer organoids showed significant growth inhibition when treated with decitabine, an epigenetic inhibitor. Noticeably, the combination of decitabine with a PARP inhibitor showed pronounced synergism in inhibiting tumor organoid growth. By employing 6-base genome multiomics and duet bioinformatic pipeline, we have identified differentially methylated genes that may be responsible for therapy resistance and tumor aggression in pancreatic cancer.

Find the venue

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Related resources

Attending from biomodal

Thao Huynh

Thao Huynh

Field Application Scientist
Rachel Aldridge

Rachel West

Regional Marketing Manager EMEA
Gianina LaChapelle

Gianina LaChapelle

Regional Marketing Manager
Carmen Guarco

Carmen Guarco

Field Application Scientist
Mark Consugar

Mark Consugar

Field Application Scientist Lead
John McShane

John McShane

Director, Business Development – East Coast USA and Canada
Jen Stone

Jennifer L. Stone, PhD

Global Head of Business Development and Customer Solutions
Páidí Creed

Páidí Creed, PhD

Vice President, Computational Technologies

Register now

AACR 2025

Stay up to date

Explore recent biomodal news and the events that we’ll be attending in the near future.

News

Events

biomodal logo

Discover

Explore

Connect

Legal

© 2025 biomodal. All rights reserved.
LinkedIn
Cambridge Epigenetix is now biomodal
Read more